

JAN. 10. 2006 2:29PM AVENTIS US PAT DEPT  
TO: US CENTRALIZED USPTO

RECEIVED  
CENTRAL FAX CENTER NO. 1075 P. 1/3  
JAN 10 2006


PTO/SB/21 (09-04)


Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/773,073
	Filing Date	February 5, 2004
	First Named Inventor	Bono-Combie et al.
	Art Unit	1625
	Examiner Name	P. Morris
	Attorney Docket Number	IVD1000 US DIV 1
Total Number of Pages in This Submission	3	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	sanofi-aventis		
Signature			
Printed name	Karen I. Krupen		
Date	January 10, 2006	Reg. No.	34,647

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 3)		
Signature		
Typed or printed name	Delia Coughlin	Date
		1/10/06

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
CENTRAL FAX CENTER

NO. 1075 P. 2/3

PATENT

JAN 10 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner: P. Morris

In re Application of  
Bono-Combie et al.

Art Unit: 1625

Application No.: 10/773,073

Filed: February 5, 2004

Title: USE OF 4-SUBSTITUTED  
TETRAHYDROPYPRIDENES FOR  
MAKING MEDICINES ACTING ON  
TGF- $\beta$ 1Telefax CertificateI hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, onJan 10, 2006  
Date of Transmission  
Signature *Bono-Combie***RESPONSE TO OFFICE COMMUNICATION**Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This amendment is response to Office Communication mailed December 13, 2005 in the above-referenced application. In the previous amendment filed on November 7, 2005, Applicants elected Group III, claim 21 drawn to a method for treating pathologies linked to an abnormal apoptotic activity to be prosecuted. Applicants further elected prion diseases as the specific disease. Applicants canceled claim 21 and submitted new claim 22, but as the December 13, 2005 Office Communication points out, new claim 22 is drawn to a method using the compound of formula I recited in claim 1 instead of the elected specific compounds according to claim 19.

This amendment rectifies this error by canceling claim 22 and submitting new claim 23 hereinbelow. Prior to examination, please amend the claims as set forth in the listing of claims beginning on page 2 of this paper.